Please note that the ANZCTR website will be unavailable from 1pm until 2pm (AEST) on Wednesday 29th May for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00915018




Registration number
NCT00915018
Ethics application status
Date submitted
4/06/2009
Date registered
4/06/2009
Date last updated
25/07/2018

Titles & IDs
Public title
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
Scientific title
A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer
Secondary ID [1] 0 0
3144A2-3005 / B1891005
Universal Trial Number (UTN)
Trial acronym
NEFERTT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Neratinib
Treatment: Drugs - Trastuzumab
Treatment: Drugs - Paclitaxel

Experimental: neratinib plus paclitaxel -

Active Comparator: trastuzumab plus paclitaxel -


Treatment: Drugs: Neratinib
Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Treatment: Drugs: Trastuzumab
Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Treatment: Drugs: Paclitaxel
Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival - Defined as the interval from the date of randomization until the first date on which recurrence or progression, or death due to any cause, is documented, censored at the last assessable evaluation or at the initiation of new anticancer therapy.
Timepoint [1] 0 0
From randomization to disease progression or death, assessed up to 5.3 years
Secondary outcome [1] 0 0
Objective Response Rate - Defined as the percentage of subjects who achieved confirmed tumor response (complete or partial response) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-Progressive Disease for non-target lesions, and no new lesions.
Timepoint [1] 0 0
From randomization to disease progression or last tumor assessment, assessed up to 5.3 years
Secondary outcome [2] 0 0
Duration of Response - Measured from the time at which measurement criteria were first met for CR or PR (whichever status was recorded first), until the date of first recurrence, disease progression (PD), or death was objectively documented, taking as a reference for PD the smallest measurements recorded since enrollment, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions.
Timepoint [2] 0 0
From first response to first PD or death, assessed up to 5.3 years after first subject randomized
Secondary outcome [3] 0 0
Clinical Benefit Rate - Defined as the proportion of patients who achieved overall tumor response (CR or PR) or SD for at least 24 weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Timepoint [3] 0 0
From randomization to disease progression or death, assessed up to 5.3 years
Secondary outcome [4] 0 0
Symptomatic or Progressive Central Nervous System (CNS) Lesions - Defined as the time interval from the date of randomization until the first date of CNS symptoms, the imaging examination shows CNS progression or is censored at the last assessable evaluation on study or prior to new anti-cancer therapy, if applicable.
If median time to Symptomatic or Progressive CNS Lesions is not estimable, cumulative incidence will be reported instead.
Timepoint [4] 0 0
From randomization to disease progression PD or last tumor assessment, assessed up to 5.3 years

Eligibility
Key inclusion criteria
- ErbB-2 positive locally recurrent or metastatic breast cancer

- Eastern Cooperative Oncology Group (ECOG) 0-2

- Measurable disease

- Availability of tumor tissue for HER2 status confirmation
Minimum age
18 Years
Maximum age
No limit
Gender
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior systemic anti-cancer therapy other than endocrine therapy for locally recurrent
or metastatic disease

- Prior erbB-2 inhibitor other than trastuzumab or lapatinib in the neoadjuvant or
adjuvant setting

- Progression/recurrence within 12 months after completion of adjuvant or neoadjuvant
therapy

- History of heart disease

- History of gastrointestinal disease

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC
Recruitment hospital [1] 0 0
The Queen Elizabeth Hospital - North Adelaide
Recruitment hospital [2] 0 0
Royal Melbourne Hospital - Parkville
Recruitment postcode(s) [1] 0 0
5011 - North Adelaide
Recruitment postcode(s) [2] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oklahoma
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
Rhode Island
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Utah
Country [19] 0 0
United States of America
State/province [19] 0 0
West Virginia
Country [20] 0 0
Bahamas
State/province [20] 0 0
CB
Country [21] 0 0
Belarus
State/province [21] 0 0
Minsk Region
Country [22] 0 0
Belarus
State/province [22] 0 0
Gomel
Country [23] 0 0
Belarus
State/province [23] 0 0
Grodno
Country [24] 0 0
Belarus
State/province [24] 0 0
Vitebsk
Country [25] 0 0
Belgium
State/province [25] 0 0
Brussels
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Plovdiv
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Sofia
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
China
State/province [29] 0 0
Guangdong
Country [30] 0 0
China
State/province [30] 0 0
Zhejiang
Country [31] 0 0
China
State/province [31] 0 0
Beijing
Country [32] 0 0
China
State/province [32] 0 0
Shanghai
Country [33] 0 0
China
State/province [33] 0 0
Tian Jin
Country [34] 0 0
Croatia
State/province [34] 0 0
Osijek
Country [35] 0 0
Croatia
State/province [35] 0 0
Zagreb
Country [36] 0 0
Denmark
State/province [36] 0 0
Copenhagen
Country [37] 0 0
France
State/province [37] 0 0
Creteil
Country [38] 0 0
France
State/province [38] 0 0
Lyon
Country [39] 0 0
France
State/province [39] 0 0
Montpellier
Country [40] 0 0
France
State/province [40] 0 0
Paris
Country [41] 0 0
France
State/province [41] 0 0
Perigueux
Country [42] 0 0
France
State/province [42] 0 0
St. Brieuc
Country [43] 0 0
France
State/province [43] 0 0
Strasbourg
Country [44] 0 0
France
State/province [44] 0 0
Tours
Country [45] 0 0
Germany
State/province [45] 0 0
Bamberg
Country [46] 0 0
Hong Kong
State/province [46] 0 0
Chai Wan
Country [47] 0 0
Hong Kong
State/province [47] 0 0
Hong Kong
Country [48] 0 0
Hong Kong
State/province [48] 0 0
Wanchai
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Hungary
State/province [50] 0 0
Kaposvar
Country [51] 0 0
Hungary
State/province [51] 0 0
Kecskemet
Country [52] 0 0
Hungary
State/province [52] 0 0
Miskolc
Country [53] 0 0
Hungary
State/province [53] 0 0
Szeged
Country [54] 0 0
India
State/province [54] 0 0
Delhi
Country [55] 0 0
India
State/province [55] 0 0
Madhya Pradesh
Country [56] 0 0
India
State/province [56] 0 0
Maharashtra
Country [57] 0 0
India
State/province [57] 0 0
Rajasthan
Country [58] 0 0
India
State/province [58] 0 0
Tamil Nadu
Country [59] 0 0
India
State/province [59] 0 0
West Bengal
Country [60] 0 0
Israel
State/province [60] 0 0
Rehovot
Country [61] 0 0
Israel
State/province [61] 0 0
Tel Aviv
Country [62] 0 0
Israel
State/province [62] 0 0
Zerifin
Country [63] 0 0
Italy
State/province [63] 0 0
Modena
Country [64] 0 0
Italy
State/province [64] 0 0
Pavia
Country [65] 0 0
Italy
State/province [65] 0 0
Roma
Country [66] 0 0
Italy
State/province [66] 0 0
Torino
Country [67] 0 0
Japan
State/province [67] 0 0
Akashi-shi
Country [68] 0 0
Japan
State/province [68] 0 0
Beppu-shi
Country [69] 0 0
Japan
State/province [69] 0 0
Bunkyo-ku
Country [70] 0 0
Japan
State/province [70] 0 0
Chiba-shi
Country [71] 0 0
Japan
State/province [71] 0 0
Fukuoka-shi
Country [72] 0 0
Japan
State/province [72] 0 0
Higashiibaraki-gun
Country [73] 0 0
Japan
State/province [73] 0 0
Hiroshima-shi
Country [74] 0 0
Japan
State/province [74] 0 0
Kagoshima-city
Country [75] 0 0
Japan
State/province [75] 0 0
Kashiwa-shi
Country [76] 0 0
Japan
State/province [76] 0 0
Kitaadachi-gun
Country [77] 0 0
Japan
State/province [77] 0 0
Kumamoto-city
Country [78] 0 0
Japan
State/province [78] 0 0
Kurume-Shi
Country [79] 0 0
Japan
State/province [79] 0 0
Matsuyama-city
Country [80] 0 0
Japan
State/province [80] 0 0
Morioka-shi
Country [81] 0 0
Japan
State/province [81] 0 0
Nagoya-shi
Country [82] 0 0
Japan
State/province [82] 0 0
Nagoya
Country [83] 0 0
Japan
State/province [83] 0 0
Niigata-shi
Country [84] 0 0
Japan
State/province [84] 0 0
Osaka-shi
Country [85] 0 0
Japan
State/province [85] 0 0
Sapporo-shi
Country [86] 0 0
Japan
State/province [86] 0 0
Sendai-city
Country [87] 0 0
Japan
State/province [87] 0 0
Tenri-shi
Country [88] 0 0
Japan
State/province [88] 0 0
Yokohama-City
Country [89] 0 0
Japan
State/province [89] 0 0
Hiroshima
Country [90] 0 0
Japan
State/province [90] 0 0
Hyogo
Country [91] 0 0
Japan
State/province [91] 0 0
Kumamoto
Country [92] 0 0
Japan
State/province [92] 0 0
Osaka
Country [93] 0 0
Japan
State/province [93] 0 0
Tochigi
Country [94] 0 0
Japan
State/province [94] 0 0
Tokyo
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Gyeonggi-do
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Korea
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Seoul/Korea
Country [98] 0 0
Latvia
State/province [98] 0 0
Liepaja
Country [99] 0 0
Latvia
State/province [99] 0 0
Riga
Country [100] 0 0
Lithuania
State/province [100] 0 0
Kaunas
Country [101] 0 0
Lithuania
State/province [101] 0 0
Vilnius
Country [102] 0 0
Malaysia
State/province [102] 0 0
Kuala Lumpur
Country [103] 0 0
Malta
State/province [103] 0 0
Floriana
Country [104] 0 0
Poland
State/province [104] 0 0
Dolnoslaskie
Country [105] 0 0
Poland
State/province [105] 0 0
Mazowieckie
Country [106] 0 0
Poland
State/province [106] 0 0
Opolskie
Country [107] 0 0
Poland
State/province [107] 0 0
Warminsko-Mazurskie
Country [108] 0 0
Poland
State/province [108] 0 0
Bialystok
Country [109] 0 0
Portugal
State/province [109] 0 0
Lisboa
Country [110] 0 0
Romania
State/province [110] 0 0
Cluj
Country [111] 0 0
Romania
State/province [111] 0 0
Dolj
Country [112] 0 0
Romania
State/province [112] 0 0
Bucuresti
Country [113] 0 0
Serbia
State/province [113] 0 0
Belgrade
Country [114] 0 0
Serbia
State/province [114] 0 0
Nis
Country [115] 0 0
Singapore
State/province [115] 0 0
Singapore
Country [116] 0 0
South Africa
State/province [116] 0 0
Eastern Cape
Country [117] 0 0
South Africa
State/province [117] 0 0
Gauteng
Country [118] 0 0
South Africa
State/province [118] 0 0
KwaZulu Natal
Country [119] 0 0
South Africa
State/province [119] 0 0
Western Cape
Country [120] 0 0
Spain
State/province [120] 0 0
Cataluna
Country [121] 0 0
Spain
State/province [121] 0 0
Galicia
Country [122] 0 0
Spain
State/province [122] 0 0
Illes Balears
Country [123] 0 0
Spain
State/province [123] 0 0
Madrid
Country [124] 0 0
Spain
State/province [124] 0 0
Malaga
Country [125] 0 0
Spain
State/province [125] 0 0
Vizcaya
Country [126] 0 0
Switzerland
State/province [126] 0 0
Aarau
Country [127] 0 0
Switzerland
State/province [127] 0 0
Thun
Country [128] 0 0
Switzerland
State/province [128] 0 0
Winterthur
Country [129] 0 0
Taiwan
State/province [129] 0 0
Taoyuan
Country [130] 0 0
Turkey
State/province [130] 0 0
Izmir
Country [131] 0 0
Ukraine
State/province [131] 0 0
Cherkassy
Country [132] 0 0
Ukraine
State/province [132] 0 0
Chernivtsi
Country [133] 0 0
Ukraine
State/province [133] 0 0
Dnipropetrovsk
Country [134] 0 0
Ukraine
State/province [134] 0 0
Donetsk
Country [135] 0 0
Ukraine
State/province [135] 0 0
Kharkiv
Country [136] 0 0
Ukraine
State/province [136] 0 0
Kyiv
Country [137] 0 0
Ukraine
State/province [137] 0 0
Lutsk
Country [138] 0 0
Ukraine
State/province [138] 0 0
Lviv
Country [139] 0 0
Ukraine
State/province [139] 0 0
Mariupil
Country [140] 0 0
Ukraine
State/province [140] 0 0
Sumy
Country [141] 0 0
United Kingdom
State/province [141] 0 0
London
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Nottingham

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Puma Biotechnology, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is investigating the effects of an experimental drug (neratinib) in combination
with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women
who have not received previous treatment for erbB-2-positive locally recurrent or metastatic
breast cancer. The study will compare the effectiveness of each regimen in shrinking tumors
and extending the lives of women with erbB-2 (HER2) positive breast cancer. The study will
also compare the safety of the two regimens and as well as the quality of life of subjects
receiving either regimen.
Trial website
https://clinicaltrials.gov/show/NCT00915018
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Puma
Address 0 0
Biotechnology
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications